BTAI (BioXcel Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BTAI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Susan E. Atkins | Director | A | — | — |
| 2026-06-17 | Javier Rodriguez | See Remarks | M | — | — |
| 2026-06-17 | Richard I Steinhart | Chief Financial Officer | M | — | — |
| 2026-06-17 | Vimal Mehta | CEO and President | M | — | — |
| 2026-06-17 | Frank Yocca | Chief Scientific Officer | M | — | — |
| 2026-05-22 | Frank Yocca | Chief Scientific Officer | MIXED | — | — |
| 2026-05-22 | Vimal Mehta | CEO and President | MIXED | — | — |
| 2026-05-22 | Javier Rodriguez | See Remarks | MIXED | — | — |
| 2026-05-22 | Richard I Steinhart | Chief Financial Officer | MIXED | — | — |
| 2026-05-07 | Vimal Mehta | CEO and President | M | — | — |
| 2026-05-07 | Javier Rodriguez | See Remarks | M | — | — |
| 2026-05-07 | Frank Yocca | Chief Scientific Officer | M | — | — |
| 2026-05-07 | Richard I Steinhart | Chief Financial Officer | M | — | — |
| 2026-03-16 | Richard I Steinhart | Chief Financial Officer | M | — | — |
| 2026-03-16 | Javier Rodriguez | See Remarks | M | — | — |
| 2026-03-16 | Vimal Mehta | CEO and President | M | — | — |
| 2026-03-16 | Frank Yocca | Chief Scientific Officer | M | — | — |
| 2026-01-12 | PETER MUELLER | Director | A | — | — |
| 2026-01-12 | MICHAEL PATRICK MILLER | Director | A | — | — |
| 2026-01-12 | Rajiv Patni | Director | A | — | — |
| 2026-01-12 | Michal Votruba | Director | A | — | — |
| 2026-01-12 | June Bray | Director | A | — | — |
| 2026-01-12 | Sandeep Laumas | Director | A | — | — |
| 2026-01-12 | DAVID J. MACK | Director | A | — | — |
| 2026-01-05 | Frank Yocca | Chief Scientific Officer | A | — | — |
| 2026-01-05 | Vimal Mehta | CEO and President | A | — | — |
| 2026-01-05 | Richard I Steinhart | Chief Financial Officer | A | — | — |
| 2026-01-05 | Javier Rodriguez | See Remarks | A | — | — |
| 2025-12-15 | Frank Yocca | Chief Scientific Officer | M | — | — |
| 2025-12-15 | Richard I Steinhart | Chief Financial Officer | M | — | — |
| 2025-12-15 | Javier Rodriguez | See Remarks | M | — | — |
| 2025-12-15 | Vimal Mehta | CEO and President | M | — | — |
| 2025-11-03 | DAVID J. MACK | Director | M | — | — |
| 2025-10-01 | DAVID J. MACK | Director | M | — | — |
| 2025-09-16 | Vimal Mehta | CEO and President | M | — | — |
| 2025-09-16 | Richard I Steinhart | Chief Financial Officer | M | — | — |
| 2025-09-16 | Javier Rodriguez | See Remarks | M | — | — |
| 2025-09-16 | Frank Yocca | Chief Scientific Officer | M | — | — |
| 2025-09-02 | DAVID J. MACK | Director | M | — | — |
| 2025-08-05 | Frank Yocca | Chief Scientific Officer | A | — | — |
| 2025-08-05 | Richard I Steinhart | Chief Financial Officer | A | — | — |
| 2025-08-05 | Javier Rodriguez | See Remarks | A | — | — |
| 2025-08-05 | Vimal Mehta | CEO and President | A | — | — |
| 2025-07-31 | DAVID J. MACK | Director | M | — | — |
| 2025-07-22 | Richard I Steinhart | Chief Financial Officer | MIXED | — | — |
| 2025-07-22 | Javier Rodriguez | See Remarks | MIXED | — | — |
| 2025-07-22 | Frank Yocca | Chief Scientific Officer | A | — | — |
| 2025-07-22 | Vimal Mehta | CEO and President | A | — | — |
| 2025-06-30 | DAVID J. MACK | Director | M | — | — |
| 2025-06-16 | Frank Yocca | Chief Scientific Officer | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO and President | 550,160 | — |
| — | Director | 534,172 | — |
| — | 10%+ Owner | 534,172 | — |
| — | 10%+ Owner | 483,067 | — |
| — | See Remarks | 26,838 | — |
| — | Chief Financial Officer | 26,335 | — |
| — | Chief Scientific Officer | 26,210 | — |
| — | Director | 20,317 | — |
| — | Director | 13,112 | — |
| — | Chief Commercial Officer | 1,580 | — |
| — | See Remarks | 1,247 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BTAI quote page; the site-wide leaderboard is on the insider transactions hub.